Table 3:

Association of baseline frailty status with optimization of guideline-directed medical therapies over 12 month follow up.

	Non-Frail (FI Class I)		Intermediate Frailty (FI Class II)		High Frailty (FI Class III)		P-int (Frailty class * time)
	Estimate (95% CI)	P-value	Estimate (95% CI)	P-value	Estimate (95% CI)	P-value
Optimal GDMT* (Triple therapy)	1.23 (1.15, 1.32)	<0.001	1.01 (0.94, 1.08)	0.78	1.07 (1.02, 1.13)	0.002	<0.001
Optimal GDMT* (Double therapy)	1.13 (1.06, 1.20)	<0.001	1.14 (1.08, 1.20)	<0.001	1.05 (1.02, 1.08)	0.008	0.007
ACE/ARB†	1.17 (0.81, 1.53)	<0.001	−0.02 (−0.35, 0.31)	0.89	−0.09 (−0.33, 0.15)	0.49	<0.001
Beta Blockers†	1.52 (122, 1.84)	<0.001	0.74 (0.49, 0.99)	<0.001	0.50 (0.34, 0.66)	<0.001	<0.001

^*Adjusted mixed effect logistic regression models were constructed to assess the association of frailty categories with the likelihood of achieving optimal triple therapy GDMT, double therapy GDMT, and initiation on MRA as noted on repeated follow up visits over time.

⁺Adjusted mixed effect linear regression models were constructed to assess the association of frailty categories with the percent of maximal dose of beta blocker and ACEi/ARB achieved as noted on repeated follow up visits over time.

All models included person ID as random effect; estimate is per 1-month. Models were adjusted for age, sex, race (white), treatment arm, baseline bmi, baseline ejection fraction, HF etiology, baseline NT-proBNP, NYHA class, Afib